Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ceapro Inc. Aeterna Zentaris and Ceapro Complete Merger Transaction June 03, 2024 From Ceapro Inc. Via GlobeNewswire Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update May 29, 2024 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Reports 2023 Financial Results and Operational Highlights April 29, 2024 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris March 28, 2024 From Ceapro Inc. Via GlobeNewswire Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company February 26, 2024 From Ceapro Inc. Via GlobeNewswire Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business February 23, 2024 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris February 15, 2024 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases December 13, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights November 29, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases November 27, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology November 07, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update August 29, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise August 25, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation July 18, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro to Participate in the Virtual Investor Summer Spotlight Series July 05, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Announces Results of 2023 Shareholders’ Meeting June 07, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update May 25, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases May 23, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration May 03, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations April 27, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights April 12, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference March 23, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society March 08, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company February 21, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event January 10, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Announces Grant of Stock Options January 04, 2023 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets December 22, 2022 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights November 09, 2022 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets November 07, 2022 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers October 13, 2022 From Ceapro Inc. Via GlobeNewswire Tickers CRPOF TSX-V:CZO Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.